文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

通过基因工程化间充质干细胞背根神经节移植治疗神经性疼痛的镇痛效果:初步结果

Analgesia for neuropathic pain by dorsal root ganglion transplantation of genetically engineered mesenchymal stem cells: initial results.

作者信息

Yu Hongwei, Fischer Gregory, Ebert Allison D, Wu Hsiang-En, Bai Xiaowen, Hogan Quinn H

机构信息

Department of Anesthesiology, Medical College of Wisconsin, 8701 Watertown Plank Rd, Milwaukee, WI, 53226, USA.

Department of Cell Biology, Neurobiology & Anatomy, Medical College of Wisconsin, 8701 Watertown Plank Rd, Milwaukee, WI, 53226, USA.

出版信息

Mol Pain. 2015 Feb 12;11:5. doi: 10.1186/s12990-015-0002-9.


DOI:10.1186/s12990-015-0002-9
PMID:25888914
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4331376/
Abstract

BACKGROUND: Cell-based therapy may hold promise for treatment of chronic pain. Mesenchymal stem cells (MSCs) are readily available and robust, and their secretion of therapeutic peptides can be enhanced by genetically engineering. We explored the analgesic potential of transplanting bone marrow-derived MSCs that have been transduced with lentivectors. To optimize efficacy and safety, primary sensory neurons were targeted by MSC injection into the dorsal root ganglia (DRGs). RESULTS: MSCs were transduced using lentivectors to express enhanced green fluorescent protein (EGFP) or to co-express the analgesic peptide glial cell line-derived neurotrophic factor (GDNF) and EGFP by a viral 2A bicistronic transgene cassette. Engineered MSCs were injected into the 4(th) lumbar (L4) and L5 DRGs of adult allogeneic rats to evaluate survival in the DRGs. MSCs were detected by immunofluorescence staining up to 2-3 weeks after injection, distributed in the extracellular matrix space without disrupting satellite glial cell apposition to sensory neurons, suggesting well-tolerated integration of engrafted MSCs into DRG tissue. To examine their potential for inhibiting development of neuropathic pain, MSCs were injected into the L4 and L5 DRGs ipsilateral to a spinal nerve ligation injury. Animals injected with GDNF-engineered MSCs showed moderate but significant reduction in mechanical allodynia and hyperalgesia compared to controls implanted with MSCs expressing EGFP alone. We also observed diminished long-term survival of allografted MSCs at 3 weeks, and the development of a highly-proliferating population of MSCs in 12% of DRGs after transplantation. CONCLUSIONS: These data indicate that genetically modified MSCs secreting analgesic peptides could potentially be developed as a novel DRG-targeted cell therapy for treating neuropathic pain. However, further work is needed to address the challenges of MSC survival and excess proliferation, possibly with trials of autologous MSCs, evaluation of clonally selected populations of MSCs, and investigation of regulation of MSC proliferation.

摘要

背景:基于细胞的疗法可能为慢性疼痛的治疗带来希望。间充质干细胞(MSCs)易于获取且生命力强,通过基因工程可增强其治疗性肽的分泌。我们探索了移植经慢病毒载体转导的骨髓源性MSCs的镇痛潜力。为了优化疗效和安全性,通过将MSCs注射到背根神经节(DRGs)中来靶向初级感觉神经元。 结果:使用慢病毒载体转导MSCs,使其表达增强型绿色荧光蛋白(EGFP),或通过病毒2A双顺反子转基因盒共表达镇痛肽胶质细胞源性神经营养因子(GDNF)和EGFP。将工程化的MSCs注射到成年同种异体大鼠的第4腰椎(L4)和L5 DRGs中,以评估其在DRGs中的存活情况。注射后2至3周通过免疫荧光染色检测到MSCs,它们分布在细胞外基质空间,未破坏卫星胶质细胞与感觉神经元的贴附,这表明移植的MSCs能很好地整合到DRG组织中。为了检验它们抑制神经性疼痛发展的潜力,将MSCs注射到脊髓神经结扎损伤同侧的L4和L5 DRGs中。与仅植入表达EGFP的MSCs的对照组相比,注射GDNF工程化MSCs的动物在机械性异常性疼痛和痛觉过敏方面有中度但显著的减轻。我们还观察到移植后3周异体移植MSCs的长期存活率降低,并且在12%的DRGs中出现了高度增殖的MSCs群体。 结论:这些数据表明,分泌镇痛肽的基因修饰MSCs有可能被开发成为一种新型的靶向DRG的细胞疗法来治疗神经性疼痛。然而,需要进一步开展工作来应对MSCs存活和过度增殖的挑战,可能需要进行自体MSCs试验、评估克隆选择的MSCs群体以及研究MSCs增殖的调控。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d49/4331376/f913ad9e4cf9/12990_2015_2_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d49/4331376/1168f49982ee/12990_2015_2_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d49/4331376/e32852a8ac9a/12990_2015_2_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d49/4331376/ca0b50dc90bd/12990_2015_2_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d49/4331376/46d036983850/12990_2015_2_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d49/4331376/f913ad9e4cf9/12990_2015_2_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d49/4331376/1168f49982ee/12990_2015_2_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d49/4331376/e32852a8ac9a/12990_2015_2_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d49/4331376/ca0b50dc90bd/12990_2015_2_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d49/4331376/46d036983850/12990_2015_2_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d49/4331376/f913ad9e4cf9/12990_2015_2_Fig5_HTML.jpg

相似文献

[1]
Analgesia for neuropathic pain by dorsal root ganglion transplantation of genetically engineered mesenchymal stem cells: initial results.

Mol Pain. 2015-2-12

[2]
Overexpression of GDNF in the uninjured DRG exerts analgesic effects on neuropathic pain following segmental spinal nerve ligation in mice.

J Pain. 2011-11

[3]
A potential anti-allodynic mechanism of GDNF following L5 spinal nerve ligation; Mitigation of NPY up-regulation in the touch sense pathway.

Neuroscience. 2015-9-24

[4]
Selective migration and engraftment of bone marrow mesenchymal stem cells in rat lumbar dorsal root ganglia after sciatic nerve constriction.

Neurosci Lett. 2006-9-11

[5]
Contribution of degeneration of motor and sensory fibers to pain behavior and the changes in neurotrophic factors in rat dorsal root ganglion.

Exp Neurol. 2004-7

[6]
Primary sensory neuron-specific interference of TRPV1 signaling by AAV-encoded TRPV1 peptide aptamer attenuates neuropathic pain.

Mol Pain. 2017

[7]
The effect of site and type of nerve injury on the expression of brain-derived neurotrophic factor in the dorsal root ganglion and on neuropathic pain behavior.

Neuroscience. 2006-2

[8]
Increased expression of HCN2 channel protein in L4 dorsal root ganglion neurons following axotomy of L5- and inflammation of L4-spinal nerves in rats.

Neuroscience. 2015-6-4

[9]
Intrathecal bone marrow stromal cells inhibit neuropathic pain via TGF-β secretion.

J Clin Invest. 2015-8-3

[10]
Prostaglandin E2 contributes to the synthesis of brain-derived neurotrophic factor in primary sensory neuron in ganglion explant cultures and in a neuropathic pain model.

Exp Neurol. 2012-1-27

引用本文的文献

[1]
Mesenchymal stem cells as a therapeutic strategy to combat oxidative stress-mediated neuropathic pain.

Bioimpacts. 2025-1-5

[2]
Advances and challenges in cell therapy for neuropathic pain based on mesenchymal stem cells.

Front Cell Dev Biol. 2025-2-21

[3]
Optimization strategies for mesenchymal stem cell-based analgesia therapy: a promising therapy for pain management.

Stem Cell Res Ther. 2024-7-18

[4]
Engineered hydrogels for peripheral nerve repair.

Mater Today Bio. 2023-5-19

[5]
Cell therapy for neuropathic pain.

Front Mol Neurosci. 2023-2-27

[6]
Dorsal root ganglia control nociceptive input to the central nervous system.

PLoS Biol. 2023-1

[7]
Can FDA-Approved Immunomodulatory Drugs be Repurposed/Repositioned to Alleviate Chronic Pain?

J Neuroimmune Pharmacol. 2021-9

[8]
In vivo survival and differentiation of Friedreich ataxia iPSC-derived sensory neurons transplanted in the adult dorsal root ganglia.

Stem Cells Transl Med. 2021-8

[9]
Stem Cells in the Treatment of Neuropathic Pain: Research Progress of Mechanism.

Stem Cells Int. 2020-12-28

[10]
Interplay of BDNF and GDNF in the Mature Spinal Somatosensory System and Its Potential Therapeutic Relevance.

Curr Neuropharmacol. 2021

本文引用的文献

[1]
Influence of intrathecal delivery of bone marrow-derived mesenchymal stem cells on spinal inflammation and pain hypersensitivity in a rat model of peripheral nerve injury.

J Neuroinflammation. 2014-9-12

[2]
The life and fate of mesenchymal stem cells.

Front Immunol. 2014-5-19

[3]
Immunogenicity of undifferentiated and differentiated allogeneic mouse mesenchymal stem cells.

J Tissue Eng. 2014-4-29

[4]
Protein synthesis and secretion in human mesenchymal cells derived from bone marrow, adipose tissue and Wharton's jelly.

Stem Cell Res Ther. 2014-4-16

[5]
Mesenchymal stem cells: immune evasive, not immune privileged.

Nat Biotechnol. 2014-3

[6]
Interferon-gamma modification of mesenchymal stem cells: implications of autologous and allogeneic mesenchymal stem cell therapy in allotransplantation.

Stem Cell Rev Rep. 2014-6

[7]
Augmenting glial cell-line derived neurotrophic factor signaling to treat painful neuropathies.

Proc Natl Acad Sci U S A. 2014-2-11

[8]
Use of genetically modified mesenchymal stem cells to treat neurodegenerative diseases.

Int J Mol Sci. 2014-1-23

[9]
Concise review: Bone marrow-derived mesenchymal stem cells change phenotype following in vitro culture: implications for basic research and the clinic.

Stem Cells. 2014-7

[10]
Mesenchymal stem cells develop tumor tropism but do not accelerate breast cancer tumorigenesis in a somatic mouse breast cancer model.

PLoS One. 2013-9-12

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索